On Tuesday, psilocybin developer Compass Pathways shared topline data from its Phase 3 program in treatment-resistant depression. We covered that readout extensively: We also reached out to researchers, practitioners, and executives across the psychedelics field to get their perspectives on the data and its potential implications. Below, we summarise their views… A common theme we heard…
